OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Rational Design of RNA Demethylase FTO Inhibitors with Enhanced Antileukemia Drug-Like Properties
Pan Xiao, Zongliang Duan, Zeyu Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9731-9752
Closed Access | Times Cited: 28
Pan Xiao, Zongliang Duan, Zeyu Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9731-9752
Closed Access | Times Cited: 28
Showing 1-25 of 28 citing articles:
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 16
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 16
A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO
Gan-qiang Lai, Yali Li, Heping Zhu, et al.
RSC Chemical Biology (2024) Vol. 5, Iss. 4, pp. 335-343
Open Access | Times Cited: 14
Gan-qiang Lai, Yali Li, Heping Zhu, et al.
RSC Chemical Biology (2024) Vol. 5, Iss. 4, pp. 335-343
Open Access | Times Cited: 14
Chemical Inhibitors Targeting the Oncogenic m6A Modifying Proteins
Yue Huang, Wenyang Xia, Ze Dong, et al.
Accounts of Chemical Research (2023) Vol. 56, Iss. 21, pp. 3010-3022
Closed Access | Times Cited: 28
Yue Huang, Wenyang Xia, Ze Dong, et al.
Accounts of Chemical Research (2023) Vol. 56, Iss. 21, pp. 3010-3022
Closed Access | Times Cited: 28
Small molecule inhibitors targeting m6A regulators
Guotai Feng, Yongya Wu, Yuan Hu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 10
Guotai Feng, Yongya Wu, Yuan Hu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 10
Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy
Lu Liu, Yuanlai Qiu, Yuying Suo, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 12, pp. 5382-5392
Open Access | Times Cited: 6
Lu Liu, Yuanlai Qiu, Yuying Suo, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 12, pp. 5382-5392
Open Access | Times Cited: 6
RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy
Jun-Xiao Shi, Zhichao Zhang, Hao-zan Yin, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Jun-Xiao Shi, Zhichao Zhang, Hao-zan Yin, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
RNA modifications in cancer
Han Wu, Shi Chen, Xiang Li, et al.
MedComm (2025) Vol. 6, Iss. 1
Open Access
Han Wu, Shi Chen, Xiang Li, et al.
MedComm (2025) Vol. 6, Iss. 1
Open Access
Discovery of Novel RNA Demethylase FTO Inhibitors Featuring an Acylhydrazone Scaffold with Potent Antileukemia Activity
Xuewu Liang, Yue Huang, Hairu Ren, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Xuewu Liang, Yue Huang, Hairu Ren, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Discovery of highly potent mTOR inhibitors aimed at suppressing the progression of acute myeloid leukemia
Yuanyuan Li, Han Qiu, Qiwen Sun, et al.
Bioorganic Chemistry (2025) Vol. 157, pp. 108287-108287
Closed Access
Yuanyuan Li, Han Qiu, Qiwen Sun, et al.
Bioorganic Chemistry (2025) Vol. 157, pp. 108287-108287
Closed Access
Development of 3-Arylaminothiophenic-2-carboxylic Acid Derivatives as New FTO Inhibitors Showing Potent Antileukemia Activities
Deyan Zhang, Lu Liu, Ming Li, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117444-117444
Closed Access
Deyan Zhang, Lu Liu, Ming Li, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117444-117444
Closed Access
Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017-present
Ze Dong, Yue Huang, Wenyang Xia, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Ze Dong, Yue Huang, Wenyang Xia, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
The m6A reader IGF2BP1 attenuates the stability of RPL36 and cell proliferation to mediate benzene hematotoxicity by recognizing m6A modification
Jingyu Wang, Xiaoli Guo, Yujiao Chen, et al.
Toxicology (2024) Vol. 503, pp. 153758-153758
Closed Access | Times Cited: 4
Jingyu Wang, Xiaoli Guo, Yujiao Chen, et al.
Toxicology (2024) Vol. 503, pp. 153758-153758
Closed Access | Times Cited: 4
Structure‐Activity Relationships of 2‐(Arylthio)benzoic Acid FTO Inhibitors
Chao Guo Yan, Qian Zhang, Pan Xiao, et al.
Israel Journal of Chemistry (2024) Vol. 64, Iss. 3-4
Closed Access | Times Cited: 3
Chao Guo Yan, Qian Zhang, Pan Xiao, et al.
Israel Journal of Chemistry (2024) Vol. 64, Iss. 3-4
Closed Access | Times Cited: 3
An update on lipophilic efficiency as an important metric in drug design
Rebecca A. Gallego, Martin P. Edwards, T. Patrick Montgomery
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 8, pp. 917-931
Closed Access | Times Cited: 3
Rebecca A. Gallego, Martin P. Edwards, T. Patrick Montgomery
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 8, pp. 917-931
Closed Access | Times Cited: 3
Small molecules that regulate the N6-methyladenosine RNA modification as potential anti-cancer agents
Noah J. Harrahill, M. Kyle Hadden
European Journal of Medicinal Chemistry (2024) Vol. 274, pp. 116526-116526
Closed Access | Times Cited: 2
Noah J. Harrahill, M. Kyle Hadden
European Journal of Medicinal Chemistry (2024) Vol. 274, pp. 116526-116526
Closed Access | Times Cited: 2
Fenamates: Forgotten treasure for cancer treatment and prevention: Mechanisms of action, structural modification, and bright future
J. J. Li, Xiaodong Wang, Honghua Zhang, et al.
Medicinal Research Reviews (2024) Vol. 45, Iss. 1, pp. 164-213
Closed Access | Times Cited: 2
J. J. Li, Xiaodong Wang, Honghua Zhang, et al.
Medicinal Research Reviews (2024) Vol. 45, Iss. 1, pp. 164-213
Closed Access | Times Cited: 2
Role of N6‐methyladenosine RNA modification in cancer
Yi Qu, Nannan Gao, Shengwei Zhang, et al.
MedComm (2024) Vol. 5, Iss. 9
Open Access | Times Cited: 2
Yi Qu, Nannan Gao, Shengwei Zhang, et al.
MedComm (2024) Vol. 5, Iss. 9
Open Access | Times Cited: 2
Recent advances in noncoding RNA modifications of gastrointestinal cancer
Tomoaki Hara, Sikun Meng, Yasuko Arao, et al.
Cancer Science (2024)
Open Access | Times Cited: 2
Tomoaki Hara, Sikun Meng, Yasuko Arao, et al.
Cancer Science (2024)
Open Access | Times Cited: 2
Therapeutic strategies to target the epitranscriptomic machinery
Denise Sighel, Eliana Destefanis, Alessandro Quattrone
Current Opinion in Genetics & Development (2024) Vol. 87, pp. 102230-102230
Open Access | Times Cited: 1
Denise Sighel, Eliana Destefanis, Alessandro Quattrone
Current Opinion in Genetics & Development (2024) Vol. 87, pp. 102230-102230
Open Access | Times Cited: 1
Combating cancer stem cells: RNA m6A methylation and small-molecule drug discovery
Honghai Zhang, Xueer Wang, Jianjun Chen, et al.
Frontiers in Drug Discovery (2024) Vol. 4
Open Access | Times Cited: 1
Honghai Zhang, Xueer Wang, Jianjun Chen, et al.
Frontiers in Drug Discovery (2024) Vol. 4
Open Access | Times Cited: 1
The role of m6A demethylases in lung cancer: diagnostic and therapeutic implications
Mengjiao Yu, Wenqian Ji, Yang Xu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Mengjiao Yu, Wenqian Ji, Yang Xu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Off-Target Inhibition of Human Dihydroorotate Dehydrogenase (hDHODH) Highlights Challenges in the Development of Fat Mass and Obesity-Associated Protein (FTO) Inhibitors
Marco Tarullo, Guillermo Fernandez Rodriguez, Alessia Iaiza, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 12, pp. 4096-4111
Open Access | Times Cited: 1
Marco Tarullo, Guillermo Fernandez Rodriguez, Alessia Iaiza, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 12, pp. 4096-4111
Open Access | Times Cited: 1
The m6A ‐independent role of epitranscriptomic factors in cancer
Guglielmo Bove, Marco Crepaldi, Sajid Amin, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 10, pp. 1705-1713
Open Access
Guglielmo Bove, Marco Crepaldi, Sajid Amin, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 10, pp. 1705-1713
Open Access
The three YTHDF paralogs and VIRMA are strong cross-histotype tumor driver candidates among m6A core genes
Eliana Destefanis, Denise Sighel, Davide Dalfovo, et al.
NAR Cancer (2024) Vol. 6, Iss. 4
Open Access
Eliana Destefanis, Denise Sighel, Davide Dalfovo, et al.
NAR Cancer (2024) Vol. 6, Iss. 4
Open Access
